Alzheimer's therapy: EMA recommends approval of amyloid antibody donanemab

So now Alzheimer's therapy: EMA recommends approval of amyloid antibody donanemab

There could soon be a second amyloid antibody available in the EU. In a renewed effort, the European Medicines Agency (EMA) has approved donanemab for the treatment of Alzheimer's disease – with restrictions.